From Rare to Prevalent

Whether it was launching the world's first gene therapy (ZOLGENSMA) or explaining the benefits of the first interchangeable biosimilar (CYLTEZO) for 7 indications, I focus on making every treatment story comprehensive and impactful. My work integrates education, treatment success, and client objectives—showcasing how thoughtful strategy can support both patient outcomes and brand goals.Take a look at the samples below to see how it's all brought together.